EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1
Abstract
Aberrant overexpression of the enhancer of zeste homolog 2 (EZH2), a histone methyltransferase inhibiting targets expression via epigenetic mechanisms, is associated with an invasive phenotype and drug resistance in ovarian cancer. Breast cancer 1 (BRCA1) gene is a well-recognized tumor suppressor, whose downregulation plays a key role in the development of ovarian cancer. In the present study, we found depletion of EZH2 increased BRCA1 protein expression and promoted its nuclear translocation, but decreased BRCA1 mRNA expression. Treatment with the Akt-1 activator insulin-like growth factor-1 (IGF-1) prevented EZH2-induced BRCA1 nuclear/cytoplasmic shuttling. Loss of BRCA1 partially rescued the effects of EZH2 downregulation on proliferation, G 2/M transition, and migration in ovarian cancer cells. However, in a cisplatin-resistant sub-line of A2780 (A2780/DDP), both EZH2 and BRCA1 were overexpressed compared with parental A2780 cells and depletion of EZH2 reduced BRCA1 expression at both mRNA and protein levels. Downregulation of EZH2 or BRCA1 sensitized A2780/DDP cells to cisplatin, whereas simultaneous inhibition of them only resulted in modest resensitization instead of showing any synergistic effect because EZH2 expressio...Continue Reading
References
Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro
Citations
Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation
Related Concepts
Related Feeds
Breast Cancer: BRCA1 & BRCA2
Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.
Breast Cancer: Chemo-Resistance
Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.